ThirtyFiveBio Limited

Investors · 4

CA

Canaan Partners✓ verifiedStamford · $500K – $20M

• Undisclosed amountbridge roundApr 2025

  AbbVie Ventures, Canaan, Mayewell Capital

  Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

32

32 Biosciences Website3 shared keywords32 Biosciences develops gut mucosal-immune science to prevent and treat gastrointestinal diseases, offering a GI discovery platform that measures metabolomic signatures of the gut mucosal-immune system and a therapeutic platform based on a Mucosal Immune Modulator (MIM) that restores and protects the gastrointestinal mucosal-immune barrier. Its lead therapeutic asset is CS-0003.

3T

3T Biosciences3 shared keywords3T Biosciences develops TCR-based immunotherapies for cancer using a proprietary platform that combines machine-learning algorithms with immunological research to identify and validate T cell receptor targets. The company creates therapeutic treatments targeting cancer and other difficult-to-treat diseases.

Companies competing with ThirtyFiveBio Limited for the same Google search keywords, organic and paid, via search-intersection analysis.

Registered name

THIRTYFIVEBIO LIMITED

Company number

13157735

Status

Active

Company type

Private limited company

Incorporated

26 Jan 2021

Registered office

99 Park Drive, Milton, Abingdon, OX14 4RY

Nature of business (SIC)

72110 — Research and experimental development on biotechnology

Accounts

last made up to 31 Dec 2025 · next due 30 Sept 2027

Confirmation statement

last made up to 25 Jan 2026 · next due 8 Feb 2027

Source: Companies House public register · retrieved 16 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.